301 Treatment of systemic lupus erythematosus patients with upadacitinib results in the coordinated inhibition of type 1 IFN-related biomarkers: biomarker analysis of the M19–130 (SLEek) phase 2 study

• Joan T Merrill,
• Alan Friedman,
• Thierry Sornasse,
• Marie-Claude Gaudreau,
• James Fann,
• Shalina Contrepois

Affiliations

Joan T Merrill

2Oklahoma Medical Research Foundation, Oklahoma City, United States of America

Alan Friedman

5AbbVie, Inc., N Chicago, IL, United States of America

Thierry Sornasse

Genentech, Inc., South San Francisco, United States of America

Marie-Claude Gaudreau

1AbbVie Inc., North Chicago, Illinois, USA

James Fann

1AbbVie Inc., North Chicago, Illinois, USA

Shalina Contrepois

1AbbVie Inc., North Chicago, Illinois, USA